Clinical Trials
138
Active:6
Completed:43
Trial Phases
4 Phases
Phase 1:26
Phase 2:37
Phase 4:13
+1 more phases
Drug Approvals
2
FDA:2
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (120 trials with phase data)• Click on a phase to view related trials
Not Applicable
44 (36.7%)Phase 2
37 (30.8%)Phase 1
26 (21.7%)Phase 4
13 (10.8%)Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
Not Applicable
Not yet recruiting
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukaemia (AML)
- Interventions
- Diagnostic Test: 5hmC BiomarkerDrug: Anthracycline
- First Posted Date
- 2025-07-11
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 112
- Registration Number
- NCT07060001
- Locations
- 🇺🇸
Houston Methodist Neal Cancer Center, Houston, Texas, United States
NALIRIFOX (Nal-IRI Plus 5-FU/LV Plus Oxaliplatin) as First-Line Treatment for Patients With Advanced Small Intestine and Appendiceal Cancers
Not Applicable
Not yet recruiting
- Conditions
- Advanced Small Intestine CancerAppendiceal Cancers
- Interventions
- Drug: Patients will be treated with NALIRIFOX (liposomal irinotecan 50 mg/m2 + 5-FU 2400 mg/m2 + LV 400 mg/m2 + oxaliplatin 60 mg/m2, IV) every 2 weeks for 12 months
- First Posted Date
- 2025-07-11
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 22
- Registration Number
- NCT07060014
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Comprehensive Multimodal Prehabilitation Alone or With Neoadjuvant Therapy Before Major Cancer Surgery
Not Applicable
Not yet recruiting
- Conditions
- Hepatopancreaticobiliary (HPB) MalignancyBladder CancerOvarian Cancer (OvCa)Kidney Cancers
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 148
- Registration Number
- NCT07050771
Ultrasound Evaluation for Baxter VASCU-GUARD Vascular Patches Post-Endarterectomy and Complications Assessment
Completed
- Conditions
- Carotid Endarterectomy (CEA) Surgical Patients
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 500
- Registration Number
- NCT07048067
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
Stem Cells for Erectile Dysfunction Post RALP
Not Applicable
Not yet recruiting
- Conditions
- Erectile DysfunctionProstate Cancer
- Interventions
- Drug: Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the ORDrug: Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's officeDrug: Placebo in clinicDrug: Placebo in the OR
- First Posted Date
- 2025-07-02
- Last Posted Date
- 2025-07-02
- Lead Sponsor
- The Methodist Hospital Research Institute
- Target Recruit Count
- 40
- Registration Number
- NCT07048314
- Locations
- 🇺🇸
Houston Methodist, Houston, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 28
- Next
News
No news found